Abbott sues J&J over new Humira rival

Get ready for a battle in the rheumatoid arthritis segment. Johnson & Johnson's Centocor unit is prepping for a launch of its new Humira competitor Simponi, and Abbott Laboratories is not amused. So unamused, in fact, that Abbott slapped J&J with allegations of patent infringement.

All in a day's work for the folks who defend Big Pharma intellectual property, right? Yes and no. Abbott's suit follows up a set of reverse accusations: Last year, Centocor and NYU sued Abbott, saying that they were entitled to patent royalties on Humira. And that case is still pending.

The new suit concerns a 2007 patent Abbott owns; the complaint asks for money and a court order preventing Centocor from continuing to use its IP. Centocor plans to "vigorously contest" the complaint, a spokesman told Bloomberg via email. "We believe we have rights to all of the intellectual property we need to market Simponi," the spokesman said. J&J just got FDA approval for the drug a month ago.

We can't pretend to know whose claims are most valid. What we do know is that billions are at stake. Humira posted 2008 sales of $4.5 billion. Analysts estimate that Simponi will be a $1 billion-plus blockbuster. And competition among TNF-alpha inhibitors--a class that includes Amgen's Enbrel and J&J's Remicade, in addition to Humira and Simponi--is already fierce.

- read the Bloomberg story

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.